TrialThe Lancet. Infectious diseases2024

Safety and immunogenicity of the intranasal H3N2 M2-deficient single-replication influenza vaccine alone or coadministered with an inactivated influenza vaccine (Fluzone High-Dose Quadrivalent) in adults aged 65-85 years in the USA: a multicentre, randomised, double-blind, double-dummy, phase 1b trial.

Joseph Eiden et al.PubMed ↗Publisher ↗

No numbers read from the abstract.